Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex.
OBJECTIVE
Studies of the neurobiological processes underlying drug addiction primarily have focused on limbic subcortical structures. Here the authors evaluated the role of frontal cortical structures in drug addiction.


METHODS
An integrated model of drug addiction that encompasses intoxication, bingeing, withdrawal, and craving is proposed. This model and findings from neuroimaging studies on the behavioral, cognitive, and emotional processes that are at the core of drug addiction were used to analyze the involvement of frontal structures in drug addiction.


RESULTS
The orbitofrontal cortex and the anterior cingulate gyrus, which are regions neuroanatomically connected with limbic structures, are the frontal cortical areas most frequently implicated in drug addiction. They are activated in addicted subjects during intoxication, craving, and bingeing, and they are deactivated during withdrawal. These regions are also involved in higher-order cognitive and motivational functions, such as the ability to track, update, and modulate the salience of a reinforcer as a function of context and expectation and the ability to control and inhibit prepotent responses.


CONCLUSIONS
These results imply that addiction connotes cortically regulated cognitive and emotional processes, which result in the overvaluing of drug reinforcers, the undervaluing of alternative reinforcers, and deficits in inhibitory control for drug responses. These changes in addiction, which the authors call I-RISA (impaired response inhibition and salience attribution), expand the traditional concepts of drug dependence that emphasize limbic-regulated responses to pleasure and reward.
D016739:Behavior, Addictive / Q000503:physiopathology; D002540:Cerebral Cortex / Q000378:metabolism / Q000503:physiopathology; D019970:Cocaine-Related Disorders / Q000378:metabolism / Q000503:physiopathology; D003192:Compulsive Behavior / Q000503:physiopathology; D004298:Dopamine / Q000502:physiology; D019788:Fluorodeoxyglucose F18; D005625:Frontal Lobe / Q000000981:diagnostic imaging / Q000378:metabolism / Q000503:physiopathology*; D006801:Humans; D008032:Limbic System / Q000503:physiopathology; D008962:Models, Theoretical; D012054:Reinforcement, Psychology; D013375:Substance Withdrawal Syndrome / Q000503:physiopathology; D019966:Substance-Related Disorders / Q000000981:diagnostic imaging / Q000503:physiopathology* / Q000523:psychology; D013577:Syndrome; D009626:Terminology as Topic; D014055:Tomography, Emission-Computed
D019788:Fluorodeoxyglucose F18; D004298:Dopamine